1. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease
- Author
-
Jadel M. Kratz, Colin Forsyth, Facundo García Bournissen, and Sergio Sosa-Estani
- Subjects
0301 basic medicine ,Chagas disease ,medicine.medical_specialty ,BENZNIDAZOLE ,030106 microbiology ,030231 tropical medicine ,Drug Resistance ,law.invention ,purl.org/becyt/ford/3.3 [https] ,03 medical and health sciences ,0302 clinical medicine ,law ,ANTIPARASITIC TREATMENT ,medicine ,Animals ,Humans ,Chagas Disease ,Pharmacology (medical) ,General Pharmacology, Toxicology and Pharmaceutics ,Intensive care medicine ,Adverse effect ,Nifurtimox ,Clinical pharmacology ,business.industry ,CHAGAS DISEASE ,Public health ,Neglected Diseases ,TRYPANOSOMA CRUZI ,General Medicine ,medicine.disease ,Trypanocidal Agents ,Regimen ,Clinical research ,Nitroimidazoles ,Benznidazole ,purl.org/becyt/ford/3 [https] ,Public Health ,business ,medicine.drug - Abstract
Introduction: Chagas disease (CD) is one of the most neglected public health problems in the Americas, where
- Published
- 2018
- Full Text
- View/download PDF